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AbstrAct
Abdominal aortic aneurysm (AAA) and aortic occlusive disease (AOD) represent 
common causes of morbidity and mortality in elderly populations which were 
previously believed to have common aetiologies. The aim of this study was to assess 
the gene expression in human AAA and AOD. We performed microarrays using aortic 
specimen obtained from 20 patients with small AAAs (≤ 55mm), 29 patients with 
large AAAs (> 55mm), 9 AOD patients, and 10 control aortic specimens obtained from 
organ donors. Some differentially expressed genes were validated by quantitative-
PCR (qRT-PCR)/immunohistochemistry. We identified 840 and 1,014 differentially 
expressed genes in small and large AAAs, respectively. Immune-related pathways 
including cytokine-cytokine receptor interaction and T-cell-receptor signalling were 
upregulated in both small and large AAAs. Examples of validated genes included 
CTLA4 (2.01-fold upregulated in small AAA, P = 0.002), NKTR (2.37-and 2.66-fold 
upregulated in small and large AAA with P = 0.041 and P = 0.015, respectively), and 
CD8A (2.57-fold upregulated in large AAA, P = 0.004). 1,765 differentially expressed 
genes were identified in AOD. Pathways upregulated in AOD included metabolic and 
oxidative phosphorylation categories. The UCP2 gene was downregulated in AOD 
(3.73-fold downregulated, validated P = 0.017). In conclusion, the AAA and AOD 
transcriptomes were very different suggesting that AAA and AOD have distinct 
pathogenic mechanisms.
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IntroductIon
Peripheral arterial diseases include a collection 
of occlusive and aneurysmal diseases affecting arteries 
outside the heart estimated to affect approximately 5% 
of adults [1]. The mechanisms responsible for ischemic 
complications of peripheral artery atherosclerosis are 
believed to be similar to those implicated in coronary 
atherosclerosis [2]. In keeping with the perceived similar 
pathogenesis of coronary and peripheral artery disease 
most of the drug therapies used in patients with these 
conditions are the same [3]. The mechanisms involved in 
abdominal aortic aneurysm (AAA) development and their 
relationship with atherosclerosis are however controversial 
[4]. Examination of human AAA biopsies has consistently 
identified concurrent intimal atherosclerosis and most 
AAAs have been considered to result from atherosclerosis 
[5, 6]. Some of the risk factors for atherosclerosis and 
AAA are however distinct, for example diabetes an 
important positive risk factor for occlusive artery disease 
is a negative risk factor for AAA [4, 5]. Dyslipidemia is 
also believed to be a less important risk factor for AAA 
than atherosclerotic occlusive disease [7]. There are also a 
number of similarities between atherosclerosis and AAA, 
including common risk factors of smoking, hypertension, 
and male gender [5, 8, 9]. The role of atherosclerosis in 
AAA therefore is currently controversial [4]. 
Examination of mechanisms involved in AAA 
has mainly relied on use of animal, particularly rodent, 
models [10]. The availability of whole genome expression 
profiling has allowed insight into a range of human 
pathologies but has been relatively sparingly applied to 
AAA and aortic atherosclerosis [11-15]. Two previous 
studies have examined the whole genome expression 
profile of human AAA specimen although sample sizes 
for these studies were relatively small totaling 7 and 10 
AAA patients, and no comparison was performed with 
atherosclerosis [11, 12]. In the current study we examined 
the whole genome expression profiles of a relatively 
large number of human aortic biopsies from subjects 
undergoing surgery to repair AAAs and to treat chronic 
lower limb ischemic due to aortic atherosclerosis (aortic 
occlusive disease, AOD). Aortic wall samples obtained 
from organ donors were used as controls. We aimed to 
compare the aortic gene expression profile of patients with 
AAA and AOD to those of older subjects with normal 
aortic histology.
results
Patient characteristics
The gene expression was initially assessed in the 
aortic biopsies of 20 patients with small AAAs (mean 
AAA diameter 53.4±2.3 mm), 29 patients with large 
AAAs (mean AAA diameter 68.4±14.3 mm), 9 patients 
with AOD (mean aortic diameter 19.6±2.6 mm), and 10 
control organ donors using microarrays (Table 1). AAA 
patients were less likely to be female compared to controls 
(small AAA 0%, large AAA 7%, controls 40%; P < 0.05), 
while AOD patients were younger compared to controls 
(mean age 61.6±9.3 vs. 68.4±4.5 years, P < 0.05). The 
validity of microarray findings was further assessed in 
biopsies obtained from 6 patients with small AAAs, 9 
patients with large AAAs, 8 AOD patients, and 6 controls 
(Table 1). AAA and AOD cases were older compared to 
controls (mean age small AAAs 69.7±3.8, large AAAs 
71.5±7.8, AOD 67.8±4.2, controls 42.7±12.5 years; P < 
0.05). Mean maximum AAA diameter was 48.5±5.7 and 
65.9±7.3 mm in patients with small and large AAAs, 
respectively.
Numerical assessment of gene expression profiles 
in small AAAs, large AAAs, and Aod
A total of 39,157 transcripts in small AAAs, 39,389 
transcripts in large AAAs, 37,904 transcripts in AOD, and 
36,725 transcripts in control samples, representing > 80% 
of the Illumina HumanHT-12 v4 Expression BeadChip 
reference list, were expressed above background and 
subjected to differential gene expression analysis. A total 
of 840 individual genes were differentially expressed (≥ 
2.0-fold, adjusted P < 0.05) in small AAAs compared 
to controls (122 upregulated and 718 downregulated 
genes; Figure 1a and 1b, respectively). A total of 1,014 
individual genes were differentially expressed (≥ 2.0 fold, 
adjusted P < 0.05) in large AAAs compared to controls 
(215 upregulated and 799 downregulated genes; Figure 
1a and 1b, respectively). 1,765 individual genes were 
differentially expressed (≥ 2.0-fold, adjusted P < 0.05) 
in AOD compare to controls (1,677 upregulated and 88 
downregulated genes; Figure 1a and 1b, respectively). 
Full lists of differentially expressed genes are given 
in Supplemental Table I, Supplemental Table II, and 
Supplemental Table III for small AAA, large AAA, and 
AOD, respectively. A preponderance of genes upregulated 
in small AAAs (100/122; 82%) were also upregulated 
in large AAAs. Approximately 47% (100/215; Figure 
1a) of the genes upregulated in large AAAs were also 
upregulated in small AAAs. In contrast only one gene 
(CXCL12) differentially expressed in AOD samples 
(1/1,765) was also differentially expressed in small (1/840) 
or large (1/1,014) AAAs (Figure 1a and 1b).
Pathways related to the differentially expressed 
genes in small and large AAA
We performed an enrichment analysis of 
differentially expressed genes with particular attention 
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Figure 2: cd8+ lymphocytes and ctlA4 in large versus small AAA. Immunohistochemical staining identifying the increased 
presence of CD8+ T cells (brown stain) in tissue from large AAA (A) versus small AAA (b) associated with lower detection of CTLA4 (red 
stain) in large (c) compared to small AAA (d); scale bar = 50 μm (A&B) & 100 μm (c&d).
Figure 1: distribution of differentially expressed genes in aortic aneurysmal and occlusive disease. Venn diagrams depict 
the overlap among differentially expressed genes in patients with small and large abdominal aortic aneurysm (AAA) and aortic occlusive 
disease (AOD). Shown are a number of upregulated (a) and downregulated (b) genes. Patients with small or large AAA or AOD were 
compared with patients without AAA (Controls), (> 2-fold difference, P value < 0.05 calculated with non-parametric Mann-Whitney test 
and corrected by Benjamini and Hochberg method).
Oncotarget12987www.impactjournals.com/oncotarget
to Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways to assess the biological contexts of these 
genes. KEGG annotations included 93% (114/122) of 
upregulated genes and 92% (661/718) of downregulated 
genes in small AAAs; and 91% (196/215) of upregulated 
genes and 95% (756/799) of downregulated genes in 
large AAA samples. The KEGG analysis revealed marked 
upregulation of genes related to immune responses in both 
small and large AAA. These pathways included cytokine-
cytokine receptor interaction (hsa04060; P = 1.15*10-
14 for small AAA, and P = 2.52*10-17 for large AAA), 
chemokine signaling pathway (hsa04062; P = 4.50*10-11 
for small AAA, and P = 3.53*10-12 for large AAA), and 
T-cell receptor signaling pathway (hsa04660; P = 4.07*10-
05 for small AAA, and P = 2.40*10-06 for large AAA) as 
shown in Table 2. Metabolic pathways (hsa01100) and 
oxidative phosphorylation (hsa00190) were found among 
the top 10 most significant KEGG categories enriched 
by downregulated genes with P = 2.30*10-22 (metabolic 
pathways) and P = 4.25*10-20 (oxidative phosphorylation) 
for small AAA; and P = 1.05*10-24 (metabolic pathways) 
and P = 8.60*10-20 (oxidative phosphorylation) for large 
AAA (Table 2).
differentially expressed genes in small and large 
AAA
Considering the marked enrichment of immune 
response categories in small and large AAA, we further 
examined a number of genes related to the immune 
response (Table 3). A majority of genes upregulated in 
small AAA were also upregulated in large AAA. Examples 
include genes coding for: pro-inflammatory cytokines 
IL1B (5.08-fold, P = 0.002 for small AAA; 3.85-fold, P = 
0.001 for large AAA), IL6 (6.28-fold, P = 0.004 for small 
AAA; 6.48-fold, P = 0.002 for large AAA), and IL8 (4.49-
fold, P = 0.005 for small AAA; 3.65-fold, P = 0.004 for 
large AAA); chemokines CXCL2 (3.35-fold, P = 0.004 for 
small AAA; 2.73-fold, P = 0.005 for large AAA), CXCL13 
(2.21-fold, P = 0.013 for small AAA; 3.09-fold, P = 0.002 
for large AAA), CCL3L3 (3.14-fold, P = 0.039 for small 
AAA; 2.59-fold, P = 0.041 for large AAA), and CCL4L2 
(2.48-fold, P = 0.021 for small AAA; 2.12-fold, P = 
0.023 for large AAA); early T-cell and B-cell activation 
cluster of differentiation (CD) antigens CD69 (2.67-fold, 
P = 0.039 for small AAA; 3.45-fold, P = 0.004 for large 
AAA) and CD19 (2.79-fold, P = 0.026 for small AAA; 
4.45-fold, P = 0.002 for large AAA), respectively; and the 
natural killer (NK) cells associated protein NKTR (2.37-
fold, P = 0.002 for small AAA; 2.66-fold, P = 0.001 for 
large AAA). An important negative regulator of T-cells 
responses, the CTLA4 gene, was exclusively upregulated 
in small AAA (2.01-fold, P = 0.018). On the other hand, 
there was increased expression of genes related to T-cell 
and B-cell responses exclusively in large AAA, including 
alpha chain of the T-cell co-receptor CD8A (2.24-fold, 
P = 0.012); the CD79A/CD79B membrane-bound dimer 
immunoglobulin in B-cells (2.76-fold, P = 0.005/3.43-
fold, P = 0.004); the receptors for Fc fragment of IgG in 
B-cells FCRL2 (2.53-fold, P = 0.002), FCRL5 (2.01-fold, 
P = 0.001), and FCRLA (3.15-fold, P = 0.009). Three 
genes (CTLA4, NKTR, and CD8A) were selected for 
further validation with quantitative real-time PCR. 
Pathways related to the differentially expressed 
genes in Aod
92% (1,550/1,677) of upregulated genes and 90% 
(79/88) of downregulated genes in AOD samples were 
annotated in the KEGG pathways. The pathways enriched 
table 1: characteristics of subjects included in this study.
characteristic discovery group Validation groupsmall AAA large AAA Aod controls small AAA large AAA Aod controls
Number 20 29 9 10 6 9 8 6
Aortic diameter (mm) 53.4±2.3 68.4±14.3 19.6±2.6 25.7±1.2 48.5±5.7 65.9±7.3 - -
Women *0 (0%) *2 (7%) 1 (11%) 4 (40%) 1 (17%) 2 (22%) 2 (25%) 2 (33%)
Age (years) 68.8±6.9 70.5±7.1 *61.6±9.3 68.4±4.5 *69.7±3.8 *71.5±7.8 *67.8±4.2 42.7±12.5
PAD 3 (15%) 5 (17%) 9 (100%) - 0 (0%) 0 (0%) 8 (100%) -
Hypertension 15 (75%) 25 (86%) 8 (89%) - 4 (67%) 6 (67%) 7 (88%) -
Diabetes mellitus 4 (20%) 7 (24%) 1 (11%) - 4 (67%) 1 (11%) 1 (13%) -
Dyslipidemia 15 (75%) 20 (69%) 8 (89%) - 6 (100%) 5 (56%) 6 (75%) -
Coronary heart disease 8 (40 %) 17 (59%) 7 (78%) - 4 (67%) 5 (56%) 4 (50%) -
Ever smoker 7 (35%) 21 (72%) 9 (100%) 5 (50%) 4 (67%) 6 (67%) 8 (100%) -
BMI (kg/m2) 28.8±3.2 26.8±4.0 23.7±2.4 22.7±9.6 34.0±5.5 25.3±3.6 21.9±4.1 -
AAA, abdominal aortic aneurysm; AOD, aortic occlusive disease; BMI, body mass index. Nominal variables are presented 
as numbers; continuous variables are presented as mean ± standard deviation. AAA or AOD were compared with controls. 
Continuous variables were compared using Mann Whitney U test; nominal variables were compared using Fisher’s exact test. 
Asterisk (*) indicates statistically significant differences compared to the control group (P < 0.05).
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table 2: top 10 KeGG pathways enriched in small and large abdominal aortic aneurysm.
category Pathway KeGG n n P value
Small AAA-upregulated genes
Cytokine-cytokine receptor interaction hsa04060 267 15 1.15*10-14
Chemokine signaling pathway hsa04062 190 11 4.50*10-11
Hematopoietic cell lineage hsa04640 88 7 3.68*10-08
NOD-like receptor signaling pathway hsa04621 62 6 1.18*10-07
Cell adhesion molecules (CAMs) hsa04514 134 7 4.15*10-07
Jak-STAT signaling pathway hsa04630 155 7 9.36*10-07
Intestinal immune network for IgA production hsa04672 50 4 4.07*10-05
T cell receptor signaling pathway hsa04660 108 5 4.07*10-05
Cytosolic DNA-sensing pathway hsa04623 56 4 5.46*10-05
Pathways in cancer hsa05200 330 7 8.39*10-05
Small AAA-downregulated genes
Ribosome hsa03010 88 27 2.50*10-26
Metabolic pathways hsa01100 1104 69 2.30*10-22
Oxidative phosphorylation hsa00190 135 26 4.25*10-20
Parkinson's disease hsa05012 133 25 3.60*10-19
Alzheimer's disease hsa05010 169 27 6.00*10-19
Huntington's disease hsa05016 185 28 6.00*10-19
Focal adhesion hsa04510 201 23 5.48*10-13
Cardiac muscle contraction hsa04260 79 15 7.66*10-12
Arrhythmogenic right ventricular cardiomyopathy hsa05412 76 11 1.65*10-07
Vascular smooth muscle contraction hsa04270 115 13 1.65*10-07
Large AAA-upregulated genes
Cytokine-cytokine receptor interaction hsa04060 267 20 2.52*10-17
Chemokine signaling pathway hsa04062 190 14 3.53*10-12
Hematopoietic cell lineage hsa04640 88 10 9.95*10-11
Primary immunodeficiency hsa05340 35 7 1.89*10-09
Cell adhesion molecules (CAMs) hsa04514 134 9 7.87*10-08
Intestinal immune network for IgA production hsa04672 50 6 6.70*10-07
Cytosolic DNA-sensing pathway hsa04623 56 6 1.15*10-06
NOD-like receptor signaling pathway hsa04621 62 6 1.86*10-06
Jak-STAT signaling pathway hsa04630 155 8 2.30*10-06
T cell receptor signaling pathway hsa04660 108 7 2.40*10-06
Large AAA-downregulated genes
Metabolic pathways hsa01100 1104 78 1.05*10-24
Huntington's disease hsa05016 185 31 3.64*10-20
Oxidative phosphorylation hsa00190 135 27 8.60*10-20
Alzheimer's disease hsa05010 169 28 2.45*10-18
Parkinson's disease hsa05012 133 25 7.70*10-18
Ribosome hsa03010 88 18 1.32*10-13
Cardiac muscle contraction hsa04260 79 16 4.25*10-12
Focal adhesion hsa04510 201 23 8.41*10-12
Vascular smooth muscle contraction hsa04270 115 17 1.27*10-10
Fatty acid metabolism hsa00071 42 10 1.70*10-08
AAA, abdominal aortic aneurysm; N, number of reference genes in the pathway; n, number of genes differentially expressed 
in pathway in small or large AAA compared to patients without AAA (Controls); > 2-fold difference, P value < 0.05 calculated 
with non-parametric Mann-Whitney test and corrected by Benjamini and Hochberg method. P value indicates the corrected 
significance of enrichment calculated from the hypergeometric test by Benjamini and Hochberg method. Pathways were 
identified using WebGestalt and were linked to the KEGG (Kyoto Encyclopedia of Genes and Genomes) website http://www.
genome.jp/kegg/.
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table 3: examples of differentially expressed genes in small and large AAA with some connection to immunity.
symbol name
small AAA large AAA
Fold change corrected P value
Fold 
change
corrected 
P value
IL1B interleukin 1, beta 5.08 0.002 3.85 0.001
IL6 interleukin 6 6.28 0.004 6.48 0.002
IL8 interleukin 8 4.49 0.005 3.65 0.004
CXCL2 chemokine (C-X-C motif) ligand 2 3.35 0.004 2.73 0.005
CXCL13 chemokine (C-X-C motif) ligand 13 2.21 0.013 3.09 0.002
CCL3L3 chemokine (C-C motif) ligand 3-like 3 3.14 0.039 2.59 0.041
CCL4L2 chemokine (C-C motif) ligand 4-like 2 2.48 0.021 2.12 0.023
CD69 CD69 molecule 2.67 0.039 3.45 0.004
CD19 CD19 antigen 2.79 0.026 4.45 0.002
NKTR natural killer-tumor recognition sequence 2.37 0.002 2.66 0.001
CTLA4 cytotoxic T-lymphocyte-associated protein 4 2.01 0.018 - -
CD8A CD8 antigen, alpha chain - - 2.24 0.012
CD79A CD79A antigen, immunoglobulin-associated alpha - - 2.76 0.005
CD79B CD79b molecule, immunoglobulin-associated beta - - 3.43 0.004
FCRL2 Fc receptor-like 2 - - 2.53 0.002
FCRL5 Fc receptor-like 5 - - 2.01 0.001
FCRLA Fc receptor-like A - - 3.15 0.009
AAA, abdominal aortic aneurysm. Differentially expressed genes were determined by comparison of patients with small 
or large AAA with patients without AAA (Controls), (> 2-fold change, P value < 0.05 calculated with non-parametric 
Mann-Whitney test and corrected by Benjamini and Hochberg method).
table 4: top 10 KeGG pathways enriched in aortic occlusive disease.
category Pathway KeGG n n P value
AOD-upregulated genes
Metabolic pathways hsa01100 1104 147 1.49*10-43
Oxidative phosphorylation hsa00190 135 49 5.68*10-35
Parkinson's disease hsa05012 133 46 7.03*10-32
Huntington's disease hsa05016 185 52 4.11*10-31
Alzheimer's disease hsa05010 169 48 5.02*10-29
Ribosome hsa03010 88 35 6.28*10-27
Focal adhesion hsa04510 201 38 1.90*10-16
Spliceosome hsa03040 128 29 8.16*10-15
Cardiac muscle contraction hsa04260 79 21 2.63*10-12
Proteasome hsa03050 48 17 2.63*10-12
AOD-downregulated genes
Cytokine-cytokine receptor interaction hsa04060 267 8 5.69*10-07
Hematopoietic cell lineage hsa04640 88 5 5.93*10-06
Chemokine signaling pathway hsa04062 190 6 8.64*10-06
Regulation of actin cytoskeleton hsa04810 216 5 2.00*10-04
Graft-versus-host disease hsa05332 42 3 3.00*10-04
Jak-STAT signaling pathway hsa04630 155 4 6.00*10-04
Pathogenic Escherichia coli infection hsa05130 59 3 6.00*10-04
NOD-like receptor signaling pathway hsa04621 62 3 6.00*10-04
Toll-like receptor signaling pathway hsa04620 101 3 2.10*10-04
Prion diseases hsa05020 35 2 3.70*10-04
AOD, aortic occlusive disease; N, number of reference genes in the pathway; n, number of genes differentially 
expressed in pathway in AOD compared to patients without AAA (Controls); > 2-fold difference, P value < 0.05 
calculated with non-parametric Mann-Whitney test and corrected by Benjamini and Hochberg method. P value 
indicates the corrected significance of enrichment calculated from the hypergeometric test by Benjamini and Hochberg 
method. Pathways were identified using WebGestalt and were linked to the KEGG (Kyoto Encyclopedia of Genes and 
Genomes) website http://www.genome.jp/kegg/.
Oncotarget12990www.impactjournals.com/oncotarget
table 5: examples of differentially expressed genes in Aod.
symbol name Function Fold change corrected P value
NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3 Complex I 2.71 0.003
NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3 Complex I 2.53 0.003
NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 Complex I 2.12 0.003
NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 Complex I 2.68 0.003
SDHA succinate dehydrogenase complex, subunit A Complex II 2.00 0.003
SDHD succinate dehydrogenase complex, subunit D Complex II 2.66 0.003
UQCRB ubiquinol-cytochrome c reductase binding protein Comples III 2.89 0.003
UQCRH ubiquinol-cytochrome c reductase hinge protein Comples III 10.76 0.003
UQCRFS1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 Comples III 2.62 0.003
COX5B cytochrome c oxidase subunit Vb Complex IV 4.62 0.003
COX6A1 cytochrome c oxidase subunit VIa polypeptide 1 Complex IV 2.06 0.008
COX6B1 cytochrome c oxidase subunit VIb polypeptide 1 Complex IV 10.45 0.003
COX6C cytochrome c oxidase subunit VIc Complex IV 3.34 0.003
COX7C cytochrome c oxidase subunit VIIc Complex V 4.32 0.003
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 Complex V 2.22 0.003
ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit Complex V 2.00 0.005
ATP5J ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6 Complex V 3.13 0.003
UCP2 uncoupling protein 2 Uncoupling -3.73 0.014
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 G/F/P 2.84 0.008
ALDH2 aldehyde dehydrogenase 2 family G/F/P 2.03 0.017
ALDH3A2 aldehyde dehydrogenase 3 family, member A2 G/F/P 2.45 0.003
ALDH9A1 aldehyde dehydrogenase 9 family, member A1 G/F/P 2.61 0.003
PDHB pyruvate dehydrogenase beta G 2.64 0.003
TPI1 triosephosphate isomerase 1 G 2.23 0.003
ACADL acyl-CoA dehydrogenase, long chain F 2.04 0.003
ACAT1 acetyl-CoA acetyltransferase 1 F 3.81 0.003
MCEE methylmalonyl CoA epimerase P 2.34 0.003
MUT methylmalonyl CoA mutase P 2.08 0.003
C1S complement component 1, s subcomponent Complement 2.08 0.044
CD46 CD46 molecule Complement 2.00 0.004
CFH complement factor H Complement 2.81 0.006
CFI complement factor I Complement 2.02 0.004
C1QBP complement component 1, q subcomponent binding protein Complement 2.10 0.003
C1RL complement component 1, r subcomponent-like Complement 2.08 0.003
C7 complement component 7 Complement 3.46 0.037
G, Glycolysis/Gluconeogenesis; F, Fatty acid metabolism; P, Propanoate metabolism; Complex I – V, mitochondrial 
complexes. Differentially expressed genes were determined by comparisons of patients of aortic occlusive disease (AOD) with 
patients without AAA (Controls), (> 2-fold change, corrected P value < 0.05 calculated with non-parametric Mann-Whitney 
test and corrected by Benjamini and Hochberg method.
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in AOD samples were distinct to those identified in AAA 
samples. In AOD, the most significant KEGG categories 
representing upregulated genes were metabolic pathways 
(hsa01100; P = 1.49*10-43) and oxidative phosphorylation 
(hsa00190; P = 5.68*10-35). Downregulated genes 
primarily fell into the immune response categories such 
as cytokine-cytokine receptor interaction (hsa04060; P = 
5.69-07) and chemokine signaling pathways (hsa04062; P 
= 8.64*10-06) as seen in Table 4.
differentially expressed genes in Aod
Inspection of genes within KEGG metabolic 
categories revealed upregulation of genes related to 
mitochondrial biogenesis that included many members 
of all five mitochondrial respiratory and ATP production 
complexes (Table 5). We also demonstrated the 
upregulation of numerous genes involved in glycolysis/
gluconeogenesis, fatty acid metabolism, and propanoate 
metabolism (Table 5). Several complement system 
genes were overexpressed such as C1S (2.08-fold, P = 
0.044), CD46 (2.00-fold, P = 0.004), CFH (2.81-fold, P 
= 0.006), CFI (2.02-fold, P = 0.004), C1QBP (2.10-fold, 
P = 0.003), C1RL (2.08-fold, P = 0.003), and C7 (3.46-
fold, P = 0.037). One important mitochondrial regulatory 
gene called mitochondrial uncoupling protein 2 (UCP2) 
was downregulated in AOD samples (-3.73-fold, P = 
0.014), (Table 5). The UCP2 gene was selected for further 
validation with quantitative real-time PCR.
real time Pcr
Expression levels of a number of genes were 
validated in biopsies from the six patients with small 
AAAs, nine patients with large AAAs, eight patients with 
AOD and six controls (Table 1). The relative expression 
of CTLA4 was significantly increased in small AAA but 
not large AAA biopsies compared to normal controls 
(Table 6). Median relative expression of CTLA4 was 
also markedly increased in small AAA versus large AAA 
biopsies (202.161 vs. 65.239, P = 0.041). The relative 
expression of CD8A was significantly increased in large 
AAA but not small AAA biopsies compared to normal 
controls (Table 6), with the median relative expression 
of CD8A in large AAA ~2-fold higher and approaching 
significance compared to small AAA (109.489 vs 61.004; 
P = 0.065). Correspondingly, immunohistochemical 
examination of AAA tissue demonstrated marked presence 
of CD8-positive T lymphocytes within the adventitia 
and outer media of a large (82mm) AAA (Figure 2A)
with limited immunostaining for CTLA4 (Figure 2C). 
In contrast there was relatively sparse presence of CD8-
positive T cells within tissue from a small (55mm) AAA 
(Figure 2B) but marked CTLA4 staining around tertiary 
table 6: Validation of genes differentially expressed in AAA or Aod by qrt-Pcr.
Gene sample n Median IQr Fold change P
CTLA4
Small AAA 6 202.161 120.109-376.825 11.12 0.002Normal control 6 18.185 10.526-24.477
Large AAA 9 65.239 17.268-176.354 3.59 0.065Normal control 6 18.185 10.526-24.477
Small AAA 6 202.161 120.109-376.825 3.10 0.041Large AAA 9 65.239 17.268-176.354
CD8A
Small AAA 6 61.004 51.980-69.598 1.60 0.132Normal control 6 38.194 18.075-46.661
Large AAA 9 109.487 61.730-176.194 2.87 0.004Normal control 6 38.194 18.075-46.661
Small AAA 6 61.004 51.980-69.598 -1.79 0.065Large AAA 9 109.487 61.730-176.194
NKTR
Small AAA 6 0.651 0.349-0.695 1.66 0.041Normal control 6 0.391 0.381-0.404
Large AAA 9 1.186 0.771-1.923 3.03 0.015Normal control 6 0.391 0.381-0.404
Small AAA 6 0.651 0.349-0.695 -1.82 0.040Large AAA 9 1.186 0.771-1.923
UCP2 AOD 8 0.729 0.545-0.737 -3.16 0.017Normal control 6 2.306 0.909-5.070
AAA, abdominal aortic aneurysm; AOD, aortic occlusive disease; N, number of samples; Median, 
median gene expression relative to reference gene (ACTB); IQR, interquartile range; P, two-sided P 
value by Mann-Whitney U test.
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lymphoid tissue at the media-adventia border (Figure 2D). 
Median relative expression of NKTR was 
significantly greater in AAA biopsies compared to 
normal controls with approximately 2- (P = 0.041) and 
3- (P = 0.015) fold increase for small and large AAAs, 
respectively (Table 6). Median relative expression 
of NKTR was also markedly increased in large AAA 
compared to small AAA biopsies (1.186 vs. 0.651, P = 
0.040).
The relative expression of UCP2 was markedly 
decreased in AOD samples compared to normal controls 
(Table 6). In subjects with AOD the UCP2 mRNA 
expression was more than 3-fold lower compared to the 
control aortic biopsies (0.739 vs. 2.306, P = 0.017). 
dIscussIon
Human AAA biopsies have been consistently shown 
to have intimal atheroma and historically AAAs have been 
considered to result from atherosclerosis [5, 6]. However 
the mechanisms involved in AAA development and its 
relationship with atherosclerosis remain controversial [4]. 
We determined the global gene expression profiles within 
biopsies of AAA and AOD using microarrays. The main 
finding from this study was that the genes differentially 
expressed in AAA and AOD were almost completely 
distinct, supporting the concept of separate developmental 
mechanisms underlying the pathogenesis of each disease 
[4]. With this in mind, global gene expression profiles 
associated with AAA and AOD will be further discussed 
separately.
AAA
A number of human and animal studies previously 
suggested a major role of immune responses in AAA 
pathogenesis [11-15] and the array findings for cytokines/
chemokines are in line with previous quantitative data 
[18]. Our results substantiate those findings, and more 
importantly, suggest also that small AAAs (≤ 55 mm) 
and large AAAs (> 55 mm) may have some distinct 
immunological characteristics. The most notable finding 
related to immunity was that the key T-cell regulatory 
gene called cytotoxic T-lymphocyte-associated protein 
4 (CTLA4 or CD152) was exclusively found to be 
upregulated in small AAAs. Moreover, our data suggests 
excessive infiltration of CD8+ T-cells in biopsies from 
large AAAs evidenced by the exclusive overexpression 
of the gene coding for the CD8A molecule and increased 
number of CD8+ T-cells found in these specimens. The 
upregulation of CTLA4 and CD8A in small AAA and large 
AAA, respectively, was confirmed by qRT-PCR and led 
us to hypothesize that downregulation of CTLA4 may 
represent a key mechanism in AAA progression which 
promotes excessive T-cell-driven immune responses in 
large AAAs. This hypothesis is supported by our finding 
of marked downregulation of the CTLA4 mRNA and the 
protein product in large AAAs compared to small AAAs 
as determined by qRT-PCR and immunohistochemistry, 
respectively. CTLA4 is a cell surface molecule that can 
down-modulate and terminate T-cell adaptive immunity 
[19]. The CD8A molecule is a constituent of the CD8 
antigen found on most cytotoxic T lymphocytes and acts 
as a co-receptor with the T-cell receptor (TCR). Previous 
immunohistochemical studies of human AAA have 
provided evidence that CD8+ T-cells infiltrating the aortic 
wall express cytotoxic mediators such as perforins, which 
generate membrane damage [20]. Other studies have 
shown that immunosuppressive agents directed exclusively 
at T-cells are capable of reducing the expansion of 
experimental AAA [21] and reduce vascular inflammation 
and aortic wall content of several inflammatory cell types 
including cytotoxic T lymphocytes in human AAA [22]. 
Taken together, the manipulation of CTLA4 levels may 
represent a novel therapeutic strategy for AAAs but this 
need examining in other contexts e.g. animal models. The 
use of CTLA4-based biologic agents such as Abatacept 
(Orencia), a novel fusion protein of the Fc region of the 
immunoglobulin IgG1 and CTLA4 designed to down-
regulate T-cells activity, is already under investigation 
as a potential therapy for other immunopathologies such 
as active rheumatoid arthritis [23-27]. Findings from the 
present study additionally demonstrate the upregulation 
of genes expressed by NK cells within large AAAs, 
such as natural killer cell group 7 sequence (NKG7) and 
natural killer-tumor recognition sequence (NKTR) genes; 
both involved in the TCR-independent innate immune 
responses. The latter was assessed and validated to be 
upregulated in large AAAs by qRT-PCR. It is possible 
that similar mechanisms involving the upregulation of 
innate immunity occur at some point between the late and 
end-stage of AAA. Findings suggest marked upregulation 
of the NKTR gene in large AAA compared to small AAA 
biopsies which is in accord with this hypothesis.
Aod
Genes differentially expressed in AOD versus 
control samples were particularly related to the metabolic 
and oxidative phosphorylation pathways which accounted 
for ~12% of all upregulated genes. In particular, we 
determined the excessive transcription of genes involved 
in mitochondrial biogenesis affecting numerous members 
of all four mitochondrial respiratory complexes as well as 
genes responsible for ATP synthesis in the mitochondrial 
complex V. Other pathways enriched included those 
related to Parkinson’s disease. Genes involved in this 
category belonging to the mitochondrial complex I were 
upregulated in AOD, contrasting the actual disruption of 
the mitochondrial complex I in Parkinson’s disease itself 
[28]. We also demonstrated the upregulation of a range 
Oncotarget12993www.impactjournals.com/oncotarget
of genes involved in glycolysis, gluconeogenesis, fatty 
acid metabolism, and propanoate metabolism. Since the 
number of overlapping genes in these metabolic pathways 
is considerable, it would be reasonable to suggest that 
overexpression of these genes may simply represent a 
metabolic maladaptation to the excessive mitochondrial 
biogenesis, as members of these bioenergetic pathways are 
tightly coordinated transcriptionally [29-31]. Upregulation 
of genes related to glucose and fatty acids metabolism is 
highly relevant to AOD. The role of an impaired glucose 
tolerance and fatty acids metabolism in atherosclerosis 
is long-documented [32, 33]. Current evidence suggests 
that the ataxia telangiectasia mutated (ATM)/mammalian 
target of rapamycin (mTOR) signaling axis may 
play an important role in suppression of macrophage 
transformation into foam cells, thus limiting the formation 
of atherosclerotic plaques [34]. Interestingly, the old 
malaria drug Chloroquine (Aralen), a lysosomotropic 
agent that activates ATM signaling, was found to be 
capable of decreasing atherosclerosis and improving 
metabolic phenotype in mice [35]. The hypothesis that 
Chloroquine may also reduce atherosclerosis in humans 
is currently under investigation [36]. The mechanisms 
responsible for upregulation of genes involved in 
mitochondrial biogenesis are not evident in the current 
study; however, we did identify downregulation of the 
UCP2 gene in AOD samples. The UCP2 protein belongs 
to a group of mitochondrial transporters that create 
proton leaks across the inner mitochondrial membrane, 
thus uncoupling respiration from ATP synthesis [37]. 
Previous studies provide evidence that uncoupling by 
UCP2 downregulates the production of reactive oxygen 
species (ROS) in endothelial and smooth muscle cells 
[38-42], whereas the UCP2 deficiency is associated with 
enhanced ROS production in the endothelium of the aorta 
[43]. Excessive ROS production is known to contribute 
to the oxidative damage of mitochondria that needs to 
be repaired to maintain intact cellular mitochondrial 
content [44]. This process is accomplished via mitophagy 
(autophagy), a selective elimination of malfunctioning 
mitochondria, which must be balanced by mitochondrial 
biogenesis to meet tissue energy requirements [45]. It 
is possible that UCP2 deficiency may, in fact, indirectly 
lead to increased mitochondrial biogenesis, explaining 
the upregulation of genes related to the metabolic and 
oxidative phosphorylation pathways in AOD. Pathways 
related to inflammation were less evident amongst 
differentially expressed genes in AOD samples. We did 
demonstrate the upregulation of a number of complement 
regulatory and effectors genes, such as complement 
regulatory protein CD46, complement factor H (CFH), 
and complement factor I (CFI) suggesting potential 
involvement of the classical complement activation 
pathway in AOD. The overexpression of the complement 
component 7 (C7) gene, a constituent of the membrane 
attack complex (MAC), may indicate the culmination of 
the alternative complement activation pathway in AOD. 
Findings are in line with previous studies that have 
suggested an important role for the complement system in 
mediating tissue injury and atherosclerosis after oxidative 
stress [46, 47].
limitation of the study
The current study has a number of limitations. The 
available sample size was relatively small especially 
for AOD although larger than any previously published 
microarrays using human aortic biopsies. In view of this 
limitation we sought to validate important findings in 
further groups of AAA and AOD biopsies. The assessment 
of independent samples helps to minimize the possibility 
that selection biases adversely affect the generalizability 
of the findings. Furthermore, we were able to obtain the 
aortic biopsies from advanced stage disease including 
AAAs measuring at least 50mm and patients needing 
aortic bypass for peripheral ischemia. Our findings 
therefore are difficult to relate to early stage vascular 
disease. The majority of available AAA and AOD biopsies 
were obtained from men limiting the relevance of our 
findings to AAA and AOD in women. Finally, the AOD 
patients were either younger (discovery group) or older 
(validation group) than their respective controls. In both 
particular comparisons of cases with controls, however, 
an important gene regulating mitochondrial biogenesis 
was found to be downregulated in AOD, suggesting that 
our findings are descriptive of the disease rather than age 
differences between cases and controls.
In conclusion, the current results demonstrate 
distinct gene expression profiles of AAA and AOD. The 
AAA transcriptome highlights an important mechanism 
controlling immune responses as opposed to the 
mitochondrial biogenesis pathways being predominantly 
associated with AOD pathology.
MAterIAls And Methods
A detailed description of all methods is presented in 
the online data supplement.
Patients
Full thickness abdominal aortic specimens were 
obtained from 49 patients undergoing open surgery to treat 
AAA, 9 patients with AOD undergoing surgery to treat 
chronic lower limb ischemia, and 10 control individuals 
(discovery group, Table 1). Maximum aortic diameter was 
50-55mm (defined as small AAA) and 56-120mm (defined 
as large AAA) in 20 and 29 AAA subjects, respectively. 
Control full thickness abdominal aortic samples were 
obtained during kidney transplant (all from heart-beating, 
brain-dead donors). The study was approved by the 
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ethics committees of the Townsville Hospital, James 
Cook University, Royal Brisbane and Women’s Hospital, 
Medical Faculty at the Technical University Dresden, 
and Leiden University Medical Center and the protocol 
conformed to ethical guidelines of Declaration of Helsinki. 
All patients gave written informed consent.
Microarrays
Microarrays were performed using the Illumina 
HumanHT-12v4 Expression BeadChip® platform as 
previously described [16]. The microarray data can be 
obtained at the Gene Expression Omnibus (GEO) database 
repository (GSE57691; http://www.ncbi.nlm.nih.gov/geo/
info/linking.html).
Analysis of array data
The raw data matrix extracted from BeadStudio was 
uploaded into the GeneSpring GX version 11.5.1 (Agilent 
Technologies Pty Ltd) software for downstream analysis 
as previously described [16]. We sought to identify genes 
with a 2-fold differential expression within the aortas of 
patients with small AAA, large AAA or AOD compared to 
donor abdominal aortas based on corrected p value < 0.05 
by the Benjamini Hochberg false discovery rate (FDR) 
method and determined by non-parametric Mann–Whitney 
U test. Genes showing ≥ 2-fold differences in expression 
between groups were considered to be significantly 
differentially expressed.
Quantitative real-time reverse transcription 
polymerase chain reaction (qrt-Pcr)
Using total RNA obtained from a further 29 patients 
with small AAAs (n = 6), large AAAs (n = 9) and AOD 
(n = 8), and another 6 organ donor biopsies (validation 
group, Table 1) we assessed the validity of microarrays 
findings using qRT-PCR as described previously [16, 17]. 
Three genes associated with AAA (CTLA4, cytotoxic 
T-lymphocyte-associated protein 4; NKTR, natural killer 
cell triggering receptor; CD8A, CD8A molecule), and the 
uncoupling protein 2 gene (UCP2) associated with AOD 
were chosen for further assessment. Mann–Whitney U test 
was performed to identify differences in expression levels 
of selected genes between small AAA, or large AAA, or 
AOD and control biopsies. Data are reported as median 
and interquartile range. All computations were performed 
using the SPSS statistical package v.17.0.2. Statistical 
significance was defined at the conventional 5% level.
Immunohistochemistry
CD8 and CTLA4 proteins were 
immunohistochemically detected on 5-µm thick paraffin 
sections of AAA tissue taken from the maximally dilated 
aneurysm body as previously described [17].
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